À propos de EUTRAF CDSS

The EUTRAF CDSS application is a mobile Clinical Decision Support System.

The EUTRAF CDSS application is a mobile Clinical Decision Support System to assess the risk of Ischemic Stroke and/or Thromboembolic Events in patients with Atrial Fibrillation. The application assess the risk of AF through the well known CHADS and CHADS-VASc score systems, as well as through novel methods developed through the EUTRAF (The European Network For Translational Research in Atrial Fibrillation) project funded by the FP7-HEALTH program of the European Commission.

These novel methods include the newly-developed CHADS-F system, multivariate Cox regression model, and the RIMARC (Ranking Instances by Maximizing the Area under the ROC Curve) model. The novel methods developed within the EUTRAF project are based on the models developed on the TRAF (Turkish Registry of Atrial Fibrillation) database comprising 550,000 patients. The CHADS-F score system is a quick method of assessing stroke or embolism risk, and stratifies patients as low-risk, medium risk, and high-risk. The multivariate Cox regression model and the RIMARC model of risk prediction are continuous models and provide a percentage value of risk of stroke or thromboembolic events.

Quoi de neuf dans la dernière version 2

Last updated on Nov 12, 2015

Minor bugfixes

Chargement de la traduction...

Informations Application supplémentaires

Dernière version

Demande EUTRAF CDSS mise à jour 2

Telechargé par

Jagannath Nagwanshi

Nécessite Android

Android 5.0+

Voir plus

EUTRAF CDSS Captures d'écran

Charegement du commentaire...
Recherche en cours...
Abonnez-vous à APKPure
Soyez le premier à avoir accès à la sortie précoce, aux nouvelles et aux guides des meilleurs jeux et applications Android.
Non merci
S'inscrire
Abonné avec succès!
Vous êtes maintenant souscrit à APKPure.
Abonnez-vous à APKPure
Soyez le premier à avoir accès à la sortie précoce, aux nouvelles et aux guides des meilleurs jeux et applications Android.
Non merci
S'inscrire
Succès!
Vous êtes maintenant souscrit à notre newsletter.